Pharmacokinetics of insulin aspart in pump-treated subjectswith type 1 diabetes: Reproducibility and effect ofage,weight, and duration of diabetes

Diabetes Care

Volumn 36, Issue 10, 2013, Pages

  Haidar, Ahmad ^a   Elleri, Daniela ^a   Kumareswaran, Kavita ^a   Leelarathna, Lalantha ^a   Allen, Janet M ^a   Caldwell, Karen ^a   Murphy, Helen R ^a   Wilinska, Malgorzata E ^a   Acerini, Carlo L ^a   Evans, Mark L ^a   Dunger, David B ^a   Nodale, Marianna ^a   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART;

AGE; BODY WEIGHT; DISEASE DURATION; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; LETTER; MAJOR CLINICAL STUDY; MALE; METABOLIC CLEARANCE RATE; REPRODUCIBILITY; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGE FACTORS; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN ASPART; MALE; RETROSPECTIVE STUDIES;

EID: 84891845082     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0485     Document Type: Letter

References (5)

1. Hedman CA, Lindström T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 2001;24:1120-1121
2. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapidacting insulin analog insulin aspart. Diabetes Care 1998;21:1910-1914
3. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care 1992;15:1484-1493
4. Gagnon-Auger M, du Souich P, Baillargeon JP, et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care 2010;33:2502-2507
5. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012;35:465-470